

USSN: 09/610,313 PP001631.0101 2300-1631.20

PATENT

CERTIFICATE OF MAILING PURSUANT TO 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, On October 8, 2007.

10/8/07

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Examiner: B. Whiteman

BARNETT et al. Group Art Unit: 1635

Serial No.: 09/610,313 | Confirmation No.: 4221

Filing Date: July 5, 2000

Title: POLYNUCLEOTIDES ENCODING

ANTIGENIC HIV TYPE C POLYPEPTIDE, POLYPEPTIDES AND USES THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sirs:

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §\$1.97 and 1.98.

- [X] Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed.
- [] No copy of the publication ______ listed on the attached Form PTO/SB/08A are being provided because the Office waives the requirement under 37 C.F.R. 1.98 (a) (2) (i) for submitting a copy of each cited U.S. patent and each U. S. patent application publication for all U.S. national patent applications filed after June 30, 2003.

USSN: 09/610,313 PP001631.0101 2300-1631.20

[]	No copies of the publications listed on the attached Form PTO/SB/08A are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No to which the above-identified application claims priority under 35 U.S.C. §120.
[]	Publication(s) listed on the attached Form PTO/SB/08A were cited in a foreign search or examination report corresponding to application serial no and dated
[]	Enclosed is a copy of a non-English publication(s) Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
[]	Enclosed is a copy of a non-English publication(s) English language publication (copy enclosed) claims priority from this non-English publication.
[]	Enclosed is an explanation of non-English publication(s) for which an English translation is not available.
[]	Enclosed is an English translation of non-English publication(s)cited in the attached Form PTO/SB/08A.
[]	Enclosed is a copy of pending patent Application Serial No
	nis Information Disclosure Statement is filed within any one of the following
time perio	ods:
[]	within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
[]	within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;
[]	before the mailing date of a first office action on the merits; or
[X	before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

USSN: 09/610,313 PP001631.0101 2300-1631.20

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Respectfully submitted,

Date: October 8, 2007

By: MI WOW

Dahna S. Pasternak

Registration No. 41,411

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Intellectual Property – R440

P.O. Box 8097

Emeryville, CA 94662-8097

Telephone: 650-493-3400 Facsimile: 650-493-3440



PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE or respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					Complete if Known
				Application Number	09/610,313
INFORMATION DISCLOSURE				Filing Date	July 5, 2000
STA	STATEMENT BY APPLICANT			First Named Inventor	BARNETT et al.
				Art Unit	1635
	(use as many sheets as necessary)			Examiner Name	B. Whiteman
Sheet	1	of	1	Attorney Docket Number	PP001631.0101 (2303-1631.20)

		Document Number	U.S. PATENT DO		
Examiner Initials*	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	For	reign Patent Do Number ⁴	cument Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т ⁶

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	1 1 (attent) integration of the production of th		T ²			
	C1	Otten, et al., "POTENT IMMUNOGENICITY OF AN HIV-1 GAG-POL FUSION DNA VACCINE DELIVERED BY IN VIVO ELECTROPORATION," Vaccine 24:4503-4509 (2006)				
			:			

Examiner	Date	
Signature	Considered	